Cronfa - Swansea University Open Access Repository

This is an author produced version of a paper published in:

*The American Journal of Human Genetics*

Cronfa URL for this paper:

http://cronfa.swan.ac.uk/Record/cronfa29412

Paper:


http://dx.doi.org/10.1016/j.ajhg.2016.06.003

This article is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Authors are personally responsible for adhering to publisher restrictions or conditions. When uploading content they are required to comply with their publisher agreement and the SHERPA RoMEO database to judge whether or not it is copyright safe to add this version of the paper to this repository.

http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/
De novo mutations in SLC1A2 and CACNA1A are important causes of epileptic encephalopathies

Epi4K Consortium*

*A complete list of authors appears at the end of the article. Correspondence to: epi4k@columbia.edu

ABSTRACT
Epileptic encephalopathies (EEs) are the most clinically important group of severe early-onset epilepsies. Next-generation sequencing has highlighted the important contribution of de novo mutations to the genetic architecture of EEs in addition to their underlying genetic heterogeneity. Our previous whole-exome sequencing study of 264 parent-child trios revealed more than 290 candidate genes in which only a single individual had a de novo variant. We sought to identify additional pathogenic variants in a subset (n=27) of these genes via targeted sequencing in an unsolved cohort of 531 individuals with a diverse range of EEs. We report 17 individuals with pathogenic variants in 7 of the 27 genes, defining a genetic etiology in 3.2% of this unsolved cohort. Our results provide definitive evidence that de novo mutations in SLC1A2, CACNA1A cause specific EEs and expand the compendium of clinically relevant genotypes for GABRB3. We also identified EEs caused by genetic variants in ALG13, DNM1, and GNAO1 and report a novel mutation in IQSEC2. Notably, recurrent mutations accounted for 7/17 of the pathogenic variants identified. As a result of high-depth coverage, parental mosaicism was identified in 2 out of 14 cases tested with mutant allelic fractions of 5-6% in the unaffected parents, carrying significant reproductive counseling implications. These results confirm that dysregulation in diverse cellular neuronal pathways causes EEs and will inform the diagnosis and management of individuals with these devastating disorders.
INTRODUCTION
Epileptic encephalopathies (EEs) frequently begin in infancy or childhood and often carry a poor prognosis. They are typically characterized by multiple seizure types and abundant epileptiform activity and are associated with developmental delay or regression. Genetic studies in recent years have established that de novo mutations are responsible for many EE phenotypes. These studies have also highlighted the marked genetic heterogeneity of the EEs, emphasizing the value of sequencing large cohorts to identify multiple individuals with mutations in the same gene to establish a specific gene’s role in disease causation. Identification of multiple individuals affected by a novel disease gene allows us to define the phenotypic spectrum of that disease and enables recognition of co-morbidities, prognosis and therapeutic response.

Our initial whole-exome sequencing (WES) study of 264 parent-child trios focused on the specific EEs of infantile spasms (IS) and Lennox-Gastaut syndrome and revealed 329 de novo variants in 305 genes. While 19 individuals had de novo mutations in previously described epilepsy genes, we also identified a statistically significant enrichment of mutations in GABRB3 (MIM: 137192) and ALG13 (MIM: 300776), establishing their role in the etiology of EEs. Similarly, DNM1 (MIM: 602377) was confirmed as an EE gene in our subsequent study. For over 290 genes, a de novo variant was identified in only a single individual with insufficient evidence to establish association with disease causation. Identifying a significant enrichment of cases with de novo variants in an individual gene is required to establish that gene’s role in EEs, ideally in combination with functional validation to support pathogenicity.

In this study, we employ massively parallel targeted sequencing of 27 candidate and recently described EE genes in a large cohort of 531 individuals with a range of EEs. We hypothesized that if the genes in which a de novo variant in the original study was identified were causative, then we may identify additional de novo variants in a
large cohort of individuals with EE. The identification of an enrichment of cases with the same genetic etiology would confirm the role of a specific gene in causing EE. We have identified individuals with a de novo mutation in 7 of the 27 genes, including several recurrent mutations. In particular, we define a new entity of SLC1A2 encephalopathy and highlight its importance as a novel glutamatergic gene for EE. We also emphasize the emerging importance and diagnostic value of CACNA1A (MIM: 601011) and GABRB3 as recurring genes causing EEs.

METHODS

Gene selection for targeted sequencing

We used various selection criteria and expert panel review to select ~10% of the 290 genes in which at least a single de novo variant was identified in the original Epi4K cohort\(^1\) for targeted sequencing. Selection criteria included: a gene in which more than one proband in the original study had a de novo variant (ALG13, GABRB3, DNM1, HDAC4); a gene recently described as causing EE (GNAO1); gene or a closely related gene family member in which mutations cause epilepsy or related disease (CACNA1A, GABRB1, GRIN1, MTOR, PIK3AP1, SLC1A2, IQSEC2, SLC35A2); gene predicted to have protein-protein interaction with a known epilepsy gene (HNRNPFI, NEDD4L); genomic location is in an epilepsy-related CNV (YWHAG); or intolerance to functional variation using the residual variation intolerance score (RVIS)\(^3\) <25% and biological plausibility based on predicted protein function (DNAJC6, EMILIN3, TRIM32, RALGAPB, VSP37A, EPHB1, NFASC, PLXNA1, SMURF1, THOC2, TRIM32, ZFHX3).

Cohort

The cohort comprised 531 individuals with EEs of unknown cause. Most of these individuals had been tested for mutations of known and novel candidate genes as well as pathogenic copy number variants\(^5-8\), so the cohort represented a highly selected group of individuals without mutations of known epilepsy genes. Detailed phenotypic characterization was performed using a validated seizure questionnaire.
together with review of medical records, EEG, imaging and investigation results. Each individual underwent phenotypic analysis and was classified into a specific epilepsy syndrome where possible.

All individuals, or their parents or legal guardians in the case of minors or those with intellectual disability, gave consent for participation in the study. The study was approved by the Human Research Ethics Committee of Austin Health, Melbourne, Australia and by the Institutional Review Board at the University of Washington.

**Molecular inversion probe design and library preparation**

Molecular inversion probes (MIPs) were designed as previously described to capture the coding exons plus a minimum of 5 base pairs of flanking sequence of intronic/exonic boundaries in each of the 27 genes. Hybridization and amplification was performed as previously described.

**Variant calling**

Libraries were sequenced on an Illumina HiSeq following the manufacturer’s instructions to generate 100 base pair paired-end reads. Raw reads were mapped to the human genome (GRCh37/hg19) using the Burrows-Wheeler Aligner (BWA v0.7.8) and variant calling was performed by the Genome Analysis Toolkit (GATK v3.1.1). Duplicate reads were marked using the Picard toolkit (v.1.113). SeattleSeq (v137) was used for annotating variants. Only variants that were predicted to affect protein sequence (missense, nonsense, frameshift, or splice variants) were assayed further. CADD, PolyPhen and GERP scores were evaluated, but no variants were excluded due to in silico predictions. Either a second independent MIP capture or Sanger sequencing was used to validate and test segregation of variants of interest. A read-depth of 50X was required for accurate variant calling.

**Criteria for pathogenicity**
Variants in recently identified EE genes were considered pathogenic if they arose *de novo* (or from a somatic mosaic parent) and had never been observed in the publically available control datasets (ExAC v0.3, ESP6500, 1000 Genomes). For novel genes, the number of *de novo* changes observed versus predicted was assessed to determine if it reached statistical significance on a per-gene basis. In cases where the inheritance was not known because of the lack of availability of parental DNA in an established EE gene, the significance of a variant was based on whether it was a recurrent mutation or convergent information provided by the *in silico* tools CADD, PolyPhen-2 and GERP. The *in silico* tools had to be in agreement (CADD >25, PolyPhen-2 >0.9 and GERP >5) to classify a variant as 'likely pathogenic'. We took a more conservative approach to novel variants with limited inheritance information for genes not yet established as causative and classified these as variants of unknown significance regardless of *in silico* predictions. Microsatellite markers were used to test the relatedness within families in which the proband had a *'de novo'* mutation and to rule out, when possible, sample duplication in the case of recurrent mutations (n=5/7 recurrent mutations tested). For one inherited GABRB3 variant (NM_000814.4:c.470C>T[p.Thr157Met]), review of the pedigree showed that the variant segregated in a family with genetic epilepsy and febrile seizures plus (GEFS+).

**Statistical Analysis**
Mutation enrichment was assayed in the new EE genes *SLC1A2* and *CACNA1A* using denovolyzeR. Briefly, using weighted per-gene mutation rates, the number of expected *de novo* mutations in our cohort of 531 individuals was calculated. The probability of observing greater than or equal *de novo* missense mutations than those expected by chance was calculated using denovolyzeR correcting for 27 genes examined.
We sequenced 27 candidate or newly described EE genes in a cohort of 531 individuals with unsolved EE representing a wide range of epilepsy syndromes (Table 1). On average, 88% of the target (27 genes) was covered at 50X or higher with a per-gene range of 69.65% (GRIN1) to 99.04% (GABRB1) (Fig. S1).

Pathogenic or likely pathogenic variants were discovered in 7 of the 27 genes (ALG13, CACNA1A, DNM1, GABRB3, GNAO1, IQSEC2, SLC1A2), accounting for 17/531 cases or 3.2% of the entire cohort (Table 2). Mutations in GABRB3 (n=7) and CACNA1A (n=4) accounted for the largest proportion of individuals. Recurrent mutations were identified in six genes (ALG13, CACNA1A, DNM1, GABRB3, GNAO1, SLC1A2). An additional six variants of uncertain significance (VOUS) were detected (Table S1).

We identified two individuals with de novo mutations in SLC1A2 (MIM: 600300), establishing this as an EE gene (p=0.0052). Previously only a single individual with IS and a de novo missense mutation was reported. SLC1A2 encodes Excitatory Amino Acid Transporter 2 (EAAT2), one of the major glutamate transporters expressed in astroglia that is responsible for clearing glutamate from the extracellular space at the synapse. One individual from our study shares the same missense mutation (NM_004171.3:c.244G>C[p.Gly82Arg]) as the original IS individual while the other person has a novel mutation (NM_004171.3:c.254T>C[p.Leu85Pro]) (Figure S2). Microsatellite testing confirmed that the two cases with the p.Gly82Arg were different individuals. These mutations cluster in the first extracellular domain of this transmembrane protein.

Our individuals with SLC1A2 mutations presented with an extremely severe phenotype with profound impairment from birth without detectable regression and seizure onset in the first week of life. The original IS individual had seizure onset in the neonatal period (Table 3). All 3 individuals had multiple seizure types with prominent myoclonic and tonic seizures as well as spasms. One (T23159) had profound growth failure with microcephaly (at age 17 years: weight 15 kg, height
and head circumference 49 cm), which was not observed in the remaining two cases.

We identified seven individuals with *GABRB3* mutations, a gene previously reported with *de novo* mutations in four individuals with LGS or IS. The seven new individuals presented with somewhat heterogeneous phenotypes of LGS (1), epilepsy with myoclonic-atonic seizures (1), and unclassified epileptic encephalopathy (4). The seventh case had features reminiscent of Dravet syndrome but could be distinguished by the absence of typical Dravet features including generalized spike wave activity, hemiclonic and focal seizures, although it is recognized that these features are not universal in Dravet syndrome (Table 4). For this case, the variant segregated in a family with genetic epilepsy and febrile seizures plus (GEFS+). Collectively, ten of the eleven individuals we found to carry a *GABRB3* *de novo* missense mutation had seizure onset by 1 year of age, occurring in the context of either preceding normal (3) or slow (6) development (details unknown for 1), whereas, one child with developmental delay had seizure onset at 12 years (Table 4). Five had severe to profound intellectual disability, three mild to moderate disability and the degree of cognitive impairment was unclear in the remaining three. Predominant seizure types were myoclonic, tonic, absence and generalized tonic-clonic seizures. One individual had epileptic spasms.

Five of the eleven pathogenic *GABRB3* variants clustered in the transmembrane domains at evolutionarily conserved sites (average GERP 5.54±0.4, nucleotide resolution). Six pathogenic variants, including the recurrent mutation, are dispersed throughout the N-terminal extracellular domain at well-conserved residues (average GERP 5.38±0.4, nucleotide resolution). One novel variant in *GABRB3* was classified as ‘likely pathogenic’ because inheritance information was limited but the amino acid change from a polar to a basic residue in the transmembrane domain (Figure S3), and a CADD score >25 and PolyPhen-2 of 0.992 (probably damaging) predicted a likely damaging effect on protein function.
Pathogenic mutations in *CACNA1A* were identified in four probands and one affected sibling. Deep sequencing of the parents with two affected children revealed that the unaffected mother was a mosaic carrier with a 6.3% mutant allelic fraction in lymphocyte-derived DNA. Two probands and the affected sibling have a recurrent mutation (NM_023035.2:c.2137G>A[p.Ala713Thr]) first identified in our original study \(^1\). This number of *de novo* missense mutations in our cohort represents a significant enrichment (\(p=8.0 \times 10^{-5}\)), providing clear evidence that *de novo* mutations in *CACNA1A* cause epileptic encephalopathy.

For the six *CACNA1A* cases, seizures began on the first day of life in five with the siblings having *in utero* movements suggestive of seizures described as “butterfly wings rapidly flapping”. Seizures were recognized by 2 hours of age in three infants (Table 5). For the remaining case, onset was at 4 weeks. Three individuals, including the sibling pair, initially had myoclonic seizures, while three presented with convulsive seizures with tonic or tonic clonic features. Multiple seizure types developed in each case and included focal, tonic and tonic-clonic seizures. Status epilepticus occurred in all, including at seizure onset in one case. A reflex component was observed in the siblings with their myoclonic seizures triggered by touch and noise and in the original case with LGS. EEG studies showed multifocal epileptiform activity in three individuals, generalized spike wave and polyspike wave in two individuals and multifocal slowing in one. Development was delayed in all with five individuals having severe ID and one moderate ID. Cerebral palsy was observed in all with variable features (Table 5). Ophthalmic findings included strabismus (1) and nystagmus (2). Motor features included ataxia (3), tremor (2) and athetosis (1).

We also identified one individual each with a recurrent mutation in *DNM1*, *GNAO1* and *ALG13* (Table S2). In the case with a *DNM1* mutation (NM_004408.2:c.709C>T[p.Arg237Trp]), one proband with an apparent *de novo* p.Arg237Trp mutation had a similarly affected sibling who carried the same
mutation. Deep sequencing of the unaffected parents confirmed somatic mosaicism in the father with a 5.5% mutant allelic fraction in blood-derived DNA. The siblings had onset of seizures at 1 month and 4 months of age with multiple seizure types, severe to profound delay and prominent movement disorder features.

A recurrent mutation in GNAO1 (NM_020988.2:c.836T>A[p.Ile279Asn]) was identified in a 2 year old boy with EOEE. All 11 reported individuals with mutations in GNAO1 are female despite GNAO1 being located on chromosome 16. Seizures may have begun in utero with unusual movements from 32 weeks gestation. Apnoeic episodes began at 26 minutes of age with 20 episodes per day. At 9 days, focal clonic seizures of the face were noted. Unusual jerky movements, involving the eyes as well, began at 4 months followed by extensor spasms. Tonic seizures developed at 16 months. Development was never normal with regression with the onset of spasms and hypsarrhythmia on EEG, and subsequent profound impairment.

We also report the eighth female with a recurrent mutation (NM_001099922.2:c.320A>G[p.Asn107Ser]) in ALG13, which is located on the X chromosome. The ALG13 p.107Ser had previously arisen de novo in seven other reported females; the father of our case was not available. Microsatellite testing confirmed our case was not related to the two individuals we reported previously. Our case showed minimal responsiveness prior to onset of tonic seizures at 1-2 months with spasms developing at 4 months. She had profound impairment with hypotonia and choreoathetoid movements. Seizures were refractory; vigabatrin increased spasms and her movement disorder. There is limited data on previous cases but common features include infantile spasms (7/7), severe to profound intellectual disability (6/7), visual impairment (2/7) and hypotonia (2/7).

Finally, we identified a 42 year old woman with a de novo nonsense mutation in IQSEC2 (NM_001111125.1:c.2203C>T[p.Gln735*]), a known cause of X-linked intellectual disability. She had preceding mild developmental delay when she...
presented at 5 years with nonconvulsive status epilepticus with absence seizures, tonic-clonic seizures and drop attacks, associated with regression. She later developed myoclonic seizures.

**DISCUSSION**

Our study of 531 individuals with unsolved EEs highlights the value of large-scale studies to secure the role of novel disease-associated genes, given the marked genetic heterogeneity underlying the EEs. We performed targeted sequencing of 27 genes drawn from more than 290 genes identified with a *de novo* variant in a cohort of 264 individuals with two specific EEs: infantile spasms and Lennox-Gastaut syndrome. We identified 17 (3.2%) cases with a causative mutation. By finding additional cases with *de novo*, and sometimes recurrent, mutations in a novel gene, we strengthen the case for pathogenicity of that gene. Our results provide evidence for *SLC1A2* as a novel cause of EE, and we refine the phenotypes of EEs associated with mutations in *GABRB3* (7/531, 1.3%) and *CACNA1A* (4/531, 0.8%), which accounted for the largest proportion of cases with mutations identified in our cohort. As larger cohorts of a new genetic EE are assembled, the efficacy (or exacerbation) of specific anti-epileptic therapies can be established. Moreover, understanding the functional consequences of specific mutations will pave the way to precision medicine.

We report conclusive evidence that mutations in *SLC1A2* cause an EE; the phenotype is extremely severe with seizure onset in the first week of life, multiple seizure types including tonic and myoclonic seizures, and profound impairment. *SLC1A2* encodes one of the major glutamate transporters, EAAT2. Mutations in *Slc1a2* in mice lead to impaired glutamate uptake causing excess glutamate and subsequent excitotoxicity. Null mice exhibit lethal spontaneous epileptic seizures with very few animals surviving beyond 13 weeks. Functional studies are required to determine if our mutations cause haploinsufficiency; if so, recently identified translational enhancers of EAAT2 may offer a novel therapeutic approach.
For *GABRB3*, our studies have now identified a total of 11 cases with a wide phenotypic spectrum, accounting for more than 1% of unsolved EEs. Seizure onset in 10/11 cases occurred in the first year of life with myoclonic, tonic, absence and generalized tonic-clonic seizures; spasms were rare. Early development could be normal or delayed; intellectual outcome varied from severe to mild. Recent case reports include two boys with an EOEE attributed to an in-frame insertion in *GABRB3* in one case and a *de novo* p.Thr287Ile substitution in the second case\textsuperscript{21; 22}.

*CACNA1A* encodes the alpha1 subunit of the Ca\textsubscript{v}2.1 P/Q-type calcium channel and was first reported as a gene for episodic ataxia type 2 (OMIM: 18500), spinocerebellar ataxia 6 (OMIM: 18036) and familial hemiplegic migraine type 1 (OMIM: 145100). *CACNA1A* is amongst the 2% most intolerant genes in the human genome\textsuperscript{3}. Although deletions that include *CACNA1A* and a single truncating mutation have been associated with EE\textsuperscript{23-25}, we show that *de novo* missense mutations can also cause a severe EE in six individuals. Seizures began on the first day of life in 5/6 cases typically including focal, tonic and tonic-clonic seizures. Myoclonic seizures were observed sometimes with a prominent reflex component. Severe ID was usual and a range of motor features were observed. All individuals had missense mutations that clustered in the transmembrane domains of this multi-pass transmembrane protein (Figure S4).

Seven of our 17 (41%) mutations were recurrent, having been reported in at least one affected individual. The *DNM1* p.Arg237Trp mutation is located in a CpG dinucleotide, a known mutation hotspot\textsuperscript{26}. The recurrence of the *SLC1A2* p.Gly82Arg mutation may be accounted for by a homopolymer stretch of guanines. Sequence context does not appear to explain the recurrence of the other mutations. The most notable example of recurrence is the p.Asn107Ser mutation in *ALG13*, which has now been reported in seven affected females. Although loss of *ALG13* function causes glycosylation defects in boys, two female individuals had normal glycosylation levels on biochemical testing\textsuperscript{13; 14}, invoking an alternative mechanism.
In 2/14 families in which we identified a mutation and were able to test both parents, we found the apparently ‘de novo’ mutation in a similarly affected sibling. Deep sequencing in both sets of parents confirmed low-level somatic mosaicism of around 6% in one parent. This finding mirrors a recent Dravet syndrome study in which one parent of a child with an apparently de novo SCN1A mutation had low, but detectable, levels of mosaicism in ~10% of cases. This has critical implications for recurrence risk calculations, reproductive choices and prenatal counseling.

There are several possible limitations to our study. First, from the phenotypic viewpoint, the discovery cohort included individuals with IS or LGS, while this cohort included much more diverse EEs (Table 1). Of the 531 individuals screened, 90 had IS and 41 LGS, meaning >75% of the cohort had other EEs. If mutations in some of these genes specifically cause IS or LGS, our cohort may be too small to detect additional mutations. However, as the majority of individuals in our cohort with a mutation did not have IS or LGS, our findings highlight the importance of screening broader populations of EEs to define the phenotypic spectrum of new genetic diseases.

From the molecular standpoint, we acknowledge that mutations may remain undetected due to suboptimal coverage of a given gene or in a given individual. Some genomic regions are less amenable to sequencing with the molecular inversion probe technology. Moreover, our conservative requirement of 50X coverage for variant calling could result in reduced sensitivity. Finally, it is important to note that not all 329 de novo variants identified in our original WES study are pathogenic. The lack of mutations in some candidate genes in our panel may be because these genes are not relevant to EE pathogenesis, or perhaps they explain a far smaller fraction of the EE population. Sequencing additional individuals and combining large datasets will facilitate identifying additional EE genes among the candidate genes from the original study.
In summary, we identified mutations in 17/531 probands, with pathogenic variants in 7/27 genes selected for targeted sequencing. There are 6 additional variants of unknown significance (Table S1) but further genetic and functional studies are required to determine if they are pathogenic. GABRB3 and CACNA1A explained the largest proportion of cases in this study providing a molecular cause for 1.3% (7/531) and 0.8% (4/531) individuals respectively; we also confirm SLC1A2 as an EE gene. Importantly, our study highlights the role of recurrent mutations, the relevance of parental mosaic transmission, and the genetic and phenotypic heterogeneity of the EEs.
Epi4K Consortium Members

Acknowledgments
Funding for this study comes from the NIH National Institute of Neurological Disorders and Stroke Center Without Walls (U01NS077274, U01NS077276, U01NS077303, U01NS077364, U01NS077275) and 2R01NS069605 (H.C.M). David Goldstein, Steve Petrou and Slavé Petrovski have interests in companies related to epilepsy precision medicine.

Web Resources
GATK, https://www.broadinstitute.org/gatk/
SeattleSeq Annotation, http://snp.gs.washington.edu/SeattleSeqAnnotation137/
REFERENCES


Table 1. Epilepsy syndromes in unsolved cohort of individuals with EEs

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epileptic encephalopathy unclassified</td>
<td>205</td>
</tr>
<tr>
<td>Infantile spasms</td>
<td>90</td>
</tr>
<tr>
<td>Epilepsy with myoclonic-atonic seizures</td>
<td>80</td>
</tr>
<tr>
<td>Lennox-Gastaut syndrome</td>
<td>41</td>
</tr>
<tr>
<td>Early onset epileptic encephalopathy (seizure onset ≤3 months)</td>
<td>33</td>
</tr>
<tr>
<td>Epilepsy aphasia syndrome</td>
<td>20</td>
</tr>
<tr>
<td>Dravet syndrome (SCN1A negative)</td>
<td>15</td>
</tr>
<tr>
<td>Febrile infection-related epilepsy syndrome</td>
<td>14</td>
</tr>
<tr>
<td>Epileptic encephalopathy with continuous diffuse spike-waves during slow-wave sleep</td>
<td>13</td>
</tr>
<tr>
<td>Epilepsy of infancy with migrating focal seizures</td>
<td>8</td>
</tr>
<tr>
<td>Atypical benign partial epilepsy of childhood</td>
<td>7</td>
</tr>
<tr>
<td>Early myoclonic encephalopathy</td>
<td>4</td>
</tr>
<tr>
<td>Early infantile epileptic encephalopathy (Ohtahara syndrome)</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total individuals</strong></td>
<td><strong>531</strong></td>
</tr>
</tbody>
</table>
Table 2. Pathogenic and likely pathogenic variants in EE genes identified in this study

<table>
<thead>
<tr>
<th>Gene</th>
<th>Proband (Sex)</th>
<th>Inheritance</th>
<th>Inferred Effect</th>
<th>GRCh37/hg19 Genomic Coordinate</th>
<th>cDNA Change</th>
<th>Protein Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SLC1A2</strong></td>
<td>EG1291 (F)</td>
<td>De novo</td>
<td>Pathogenic a</td>
<td>chr11:g.35336636 NM_004171.3:c.244G&gt;C</td>
<td>NM_004171.3:c.244G&gt;C</td>
<td>p.Gly82Arg</td>
</tr>
<tr>
<td>EG1291 (F)</td>
<td>De novo</td>
<td>Pathogenic</td>
<td>chr11:g.35336626 NM_004171.3:c.254T&gt;C</td>
<td>p.Leu85Pro</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GABRB3</strong></td>
<td>EG0254 (M)</td>
<td>De novo</td>
<td>Pathogenic a</td>
<td>chr15:g.26866564 NM_000814.4:c.358G&gt;A</td>
<td>p.Asp120Asn</td>
<td></td>
</tr>
<tr>
<td>EG0258 (M)</td>
<td></td>
<td>Segregates with GEFS+ family</td>
<td>Chr15:g.26828553 NM_000814.4:c.470C&gt;T</td>
<td>p.Thr157Met</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T22598 (F)</td>
<td>De novo</td>
<td>Pathogenic b</td>
<td>chr15:g.26825603 NM_000814.4:c.545A&gt;T</td>
<td>p.Tyr182Phe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T25111 (F)</td>
<td>De novo</td>
<td>Pathogenic</td>
<td>chr15:g.26812818 NM_000814.4:c.745C&gt;A</td>
<td>p.Gln249Lys</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG1542 (M)</td>
<td>De novo</td>
<td>Pathogenic</td>
<td>chr15:g.26812796 NM_000814.4:c.767T&gt;A</td>
<td>p.Leu256Gln</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T23950 (F)</td>
<td>Unknown</td>
<td>Likely pathogenic</td>
<td>chr15:g.26806281 NM_000814.4:c.878T&gt;A</td>
<td>p.Leu293His</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T25708 (M)</td>
<td>De novo</td>
<td>Pathogenic</td>
<td>chr15:g.26806246 NM_000814.4:c.913G&gt;A</td>
<td>p.Ala305Thr</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CACNA1A</strong></td>
<td>EG1371 (M)</td>
<td>De novo</td>
<td>Pathogenic</td>
<td>chr19:g.13566019 NM_023035.2:c.301G&gt;C</td>
<td>p.Glu101Gln</td>
<td></td>
</tr>
<tr>
<td>T21924 (F)</td>
<td>Unknown, father unavailable</td>
<td>VOUS c</td>
<td>chr19:g.13476262 NM_023035.2:c.653C&gt;T</td>
<td>p.Ser218Leu</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T23039 (F)</td>
<td>De novo</td>
<td>Pathogenic a</td>
<td>chr19:g.13414398 NM_023035.2:c.2137G&gt;A</td>
<td>p.Ala713Thr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T24139 (M)</td>
<td>Mosaic mother</td>
<td>Pathogenic a</td>
<td>chr19:g.13414398 NM_023035.2:c.2137G&gt;A</td>
<td>p.Ala713Thr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG1519 (F)</td>
<td>De novo</td>
<td>Pathogenic</td>
<td>chr19:g.13368235 NM_023035.2:c.4531G&gt;T</td>
<td>p.Ala1511Ser</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DNM1</strong></td>
<td>T24107 (F)</td>
<td>Mosaic parent</td>
<td>Pathogenic a</td>
<td>chr9:g.130982480 NM_004408.2:c.709C&gt;T</td>
<td>p.Arg237Trp</td>
<td></td>
</tr>
<tr>
<td><strong>GNAO1</strong></td>
<td>T25023 (M)</td>
<td>De novo</td>
<td>Pathogenic a</td>
<td>chr16:g.56385408 NM_020988.2:c.836T&gt;A</td>
<td>p.Ile279Asn</td>
<td></td>
</tr>
<tr>
<td><strong>IQSEC2</strong></td>
<td>T17563 (F)</td>
<td>De novo</td>
<td>Pathogenic</td>
<td>chrX:g.53279555 NM_001111125.1:c.2203C&gt;T</td>
<td>p.Gln735*</td>
<td></td>
</tr>
<tr>
<td><strong>ALG13</strong></td>
<td>T22647 (F)</td>
<td>Unknown, father unavailable</td>
<td>Pathogenic a</td>
<td>chrX:g.110928268 NM_001099922.2:c.320A&gt;G</td>
<td>p.Asn107Ser</td>
<td></td>
</tr>
</tbody>
</table>

DS, Dravet syndrome; EE, epileptic encephalopathy; EIEE, early infantile epileptic encephalopathy; EIMFS, epilepsy of infancy with migrainous features; GM, myoclonic encephalopathy; EOEE, early onset epileptic encephalopathy; GEFS+, Generalized epilepsy with febrile seizures plus; ID, intellectual disability; IS, infantile spasms; LGS, Lennox-Gastaut syndrome; MAE, epilepsy with myoclonic-atactic seizures; SGE, symptomatic generalised epilepsy; VOUS, variant of unknown significance.

a Recurrent mutation that has previously been reported as causing EE. b Previously reported 29. c Clinical Variant (rs121908225) associated with focal epilepsy with progressive cerebellar ataxia.
### Table 3. Clinical features of individuals with SLC1A2 mutations

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Age</th>
<th>Gender</th>
<th>Epilepsy syndrome</th>
<th>Development prior to seizure onset</th>
<th>Age of seizure onset</th>
<th>Seizure type at onset</th>
<th>Development after seizure onset</th>
<th>Other seizure types</th>
<th>Age of seizure offset</th>
<th>EEG</th>
<th>Neuroimaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>T23159</td>
<td>17y F</td>
<td>EME</td>
<td>Never normal</td>
<td>2d</td>
<td>Myotonic (virtually continuous multifocal twitching, particularly in sleep)</td>
<td>Profound ID</td>
<td>Tonic (generalised and focal) Myoclonic SE Possible NCSE</td>
<td>Ongoing</td>
<td>Multifocal Slow background</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG1291</td>
<td>6y F</td>
<td>EOE</td>
<td>Never normal</td>
<td>5d</td>
<td>Epileptic spasms</td>
<td>Profound ID</td>
<td>Myoclonic Myoclonic SE Tonic Tonic-clonic Focal</td>
<td>Ongoing</td>
<td>Multifocal (no hypsarrhythmia)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Individuals identified in this cohort**

**Individuals identified in Epi4K Consortium 2013**

**ACTH**, adrenocorticotropic hormone; **ADHD**, attention deficit hyperactivity disorder; **AZD**, acetazolamide; **CBZ**, carbamazepine; **CC**, corpus callosum; **CLB**, cllobaza m; **CLZ**, clorazepate; **CT**, cybermagnetic resonance imaging; **CSE**, convulsive status epilepticus; **CZP**, clonazepam; **D**, days; **DZP**, diazepam; **EE**, epileptic encephalopathy; **EIEE**, early infantile epileptic encephalopathy; **EME**, early myoclonic encephalopathy; **EOEE**, early onset epileptic encephalopathy; **ETX**, ethosuximide; **F**, female; **FBM**, felbamate; **FIAS**, focal impaired awareness seizure; **FGH**, febrile gluteal hypotonia; **GORD**, gastro-oesophageal reflux disease; **GPFA**, generalised paroxysmal fast activity; **GSW**, generalised spike wave; **h**, hours; **I**, intellectual disability; **IS**, infantile spasms; **KD**, ketogenic diet; **Kg**, kilograms; **L**, left; **LCM**, lacosamide; **LEV**, levetiracetam; **LTG**, lamotrigine; **LGS**, Lennox-Gastaut Syndrome; **M**, male; **MAD**, modified Atkins diet; **MDZ**, midazolam; **mth**, months; **NCSE**, non-convulsive status epilepticus; **NPSLE**, neuropsychiatric lupus syndrome; **OCBZ**, oxcarbazepine; **PB**, phenobarbitone; **PFA**, paroxysmal fast activity; **PHT**, phenytoin; **PM**, primidone; **PSW**, slow spike wave; **PEG**, percutaneous endoscopic gastrostomy; **PET**, positron emission tomography; **PMI**, postmortem imaging; **PMR**, periventricular white matter; **PSW**, slow wave; **R**, right; **RFM**, rufinamide; **sec**, seconds; **SE**, status epilepticus; **SPECT**, single-photon emission computed tomography; **STP**, stiripentol; **SSW**, slow spike wave; **TPM**, topiramate; **w**, weeks; **y**, years; **ZNS**, zonisamide

* medications current at last follow-up underlined
### Table 4. Clinical features of individuals with GABRB3 mutations

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Gender</th>
<th>Age</th>
<th>Epilepsy syndrome</th>
<th>Development prior to seizure onset</th>
<th>Age of seizure onset</th>
<th>Seizure type at onset</th>
<th>Development after seizure onset</th>
<th>Other seizure types</th>
<th>Age of seizure offset</th>
<th>EEG</th>
<th>Neuroimaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>T25111</td>
<td>F</td>
<td>1y</td>
<td>EE</td>
<td>Delayed at 6m</td>
<td>12y</td>
<td>Tonic-clonic</td>
<td>Severe ID</td>
<td>Absence</td>
<td>Ongoing</td>
<td></td>
<td>Normal</td>
</tr>
<tr>
<td>T22598</td>
<td>M</td>
<td>2y</td>
<td>SUDEP</td>
<td>Delayed</td>
<td>6mth</td>
<td>Facial grimace and horizontal head shaking with retained awareness</td>
<td>Delayed Tonic-clonic Focal with retained awareness</td>
<td>Focal SE Tonic Atypical absence Tonic</td>
<td>Ongoing at death</td>
<td>Multifocal Slow background</td>
<td></td>
</tr>
<tr>
<td>T25708</td>
<td>M</td>
<td>14y</td>
<td>LGS</td>
<td>Never normal</td>
<td>5mth</td>
<td>Improved facial expression, choking, stiffening of arms, eye rolling</td>
<td>Severe ID Tonic-clonic Atypical absence Tonic Myoclonic</td>
<td>Episodic kicking or thrashing of limbs and body</td>
<td>Ongoing</td>
<td>Almost continuous GSW Slow background Multifocal SSW GPF A</td>
<td></td>
</tr>
<tr>
<td>T23956</td>
<td>M</td>
<td>7y</td>
<td>EORE</td>
<td>Never normal</td>
<td>1mth</td>
<td>Myoclonic</td>
<td>Profound ID Tonic Focal motor Clonic</td>
<td>Unknown (lost to follow up)</td>
<td>Multifocal sharp waves</td>
<td></td>
<td>Cortical atrophy Thin CC Increased T2 in globus pallidus</td>
</tr>
<tr>
<td>E00258</td>
<td>M</td>
<td>5y</td>
<td>Dravet syndrome-like</td>
<td>Normal</td>
<td>8mth</td>
<td>Febrile Tonic-clonic</td>
<td>Mild ID Delayed by 2.5y Tonic-clonic Absence Myoclonic Tonic</td>
<td>Spasms Focal motor Tonic</td>
<td>Ongoing</td>
<td>Frontal, temporal and central sharp waves Frontal and temporal R sharp waves</td>
<td>Normal</td>
</tr>
<tr>
<td>E01542</td>
<td>M</td>
<td>3y</td>
<td>EORE</td>
<td>Unknown</td>
<td>1d</td>
<td>Tonic-clonic</td>
<td>Delayed by 3mth Severe ID Tonic</td>
<td>Multifocal sharp waves</td>
<td>Ongoing</td>
<td>Hypersynchrony Polymorphous delta intermixed with polyspikes Diffuse background slowing Hypomyelination</td>
<td></td>
</tr>
<tr>
<td>E00254</td>
<td>M</td>
<td>12y</td>
<td>MAE</td>
<td>Normal</td>
<td>1y</td>
<td>Febrile Tonic-clonic</td>
<td>Mild ID Delayed by 2.5y Myoclonic-atomic Absence</td>
<td>Unknown</td>
<td>2.5-3Hz GSW Diffuse slowing</td>
<td>Normal</td>
<td></td>
</tr>
</tbody>
</table>

**Individuals identified in Epilepsy Phenome/Genome et al. 2013**

<table>
<thead>
<tr>
<th></th>
<th>Gender</th>
<th>Age</th>
<th>Epilepsy syndrome</th>
<th>Development prior to seizure onset</th>
<th>Age of seizure onset</th>
<th>Seizure type at onset</th>
<th>Development after seizure onset</th>
<th>Other seizure types</th>
<th>Age of seizure offset</th>
<th>EEG</th>
<th>Neuroimaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>d</td>
<td>F</td>
<td>13y</td>
<td>IS</td>
<td>Normal</td>
<td>5mth</td>
<td>Infantile Spasms</td>
<td>Mild delay Myoclonic Focal impaired awareness</td>
<td>Unknown</td>
<td>Hypersynchrony evolved from multifocal discharges</td>
<td>Background slowing</td>
<td>Normal</td>
</tr>
<tr>
<td>g</td>
<td>F</td>
<td>18y</td>
<td>LGS</td>
<td>Delayed</td>
<td>10mth</td>
<td>Focal impaired awareness</td>
<td>Severe ID Tonic-clonic CSE</td>
<td>Unknown</td>
<td>Generalised slowing GSW Bilateral synchronous L-R sharp waves or spikes L temporal paroxysmal features</td>
<td>Bilateral independent</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACTH, adrenocorticotropic hormone; ADHD, attention deficit hyperactivity disorder; AZD, acetazolamide; CBZ, carbamazepine; CC, corpus callosum; CLB, clobazam; GLZ, clorgyline; GORD, gastro-oesophageal reflux disease; GPFA, generalised paroxysmal fast activity; GSW, generalised spike wave; h, hours; ID, intellectual disability; IS, infantile spasms; IS, intravenous; LGS, Lennox-Gastaut Syndrome; M, male; MAD, modified Atkins diet; MDZ, midazolam; mth, months; NCSE, non-convulsive status epilepticus; NZP, nitrazepam; OCBZ, oxcarbazepine; PB, phenobarbitone; PFA, paroxysmal fast activity; PHT, phenytoin; PRM, primidone; PSW, polyspike wave; PEG, percutaneous endoscopic gastrostomy; SPECT, single-photon emission computed tomography; STP, stiripentol; SSW, slow spike wave; TPM, topiramate; VNS, vagus nerve stimulation; VPA, valproate; w, weeks; y, years; ZNS, zonisamide

*medications current at last follow-up underlined*
Table 5. Clinical features of individuals with CACNA1A mutations

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Gender</th>
<th>Epilepsy syndrome</th>
<th>Development prior to seizure onset</th>
<th>Age of seizure onset</th>
<th>Seizure type at onset</th>
<th>Development after seizure onset</th>
<th>Other seizure types</th>
<th>Age of seizure offset</th>
<th>EEG</th>
<th>Neuroimaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>T24139 (brother of T24629)</td>
<td>5y</td>
<td>M</td>
<td>EDEE</td>
<td>Initially diagnosed with hyperekplexia</td>
<td>C-PAP ventilation for 4h after birth</td>
<td>At birth (abnormal movements in utero)</td>
<td>Jittery movements at birth, myoclonic seizures in NICU</td>
<td>Regression at 2y</td>
<td>Severe ID</td>
<td>Tonic-clonic</td>
<td>Ongoing Multifocal Diffuse slowing R tempoparietal spikes</td>
</tr>
<tr>
<td>T24629 (sister of T24629)</td>
<td>15y</td>
<td>F</td>
<td>EDEE</td>
<td>Initially diagnosed with hyperekplexia</td>
<td>Delayed</td>
<td>5h (abnormal movements in utero)</td>
<td>Focal myoclonic</td>
<td>Severe ID</td>
<td>Tonic-clonic</td>
<td>Ongoing Multifocal Beta activity R-L sharp and slow waves</td>
<td></td>
</tr>
<tr>
<td>T23039</td>
<td>7y</td>
<td>F</td>
<td>EDEE</td>
<td>Normal up to 4th</td>
<td>1-2h</td>
<td>Tonic-clonic</td>
<td>Severe ID</td>
<td>Myoclonic Focal CSE Focal impaired awareness</td>
<td>Ongoing</td>
<td>GSW PSW Mild slowing bi-mid central frontal activity</td>
<td></td>
</tr>
<tr>
<td>EG1371</td>
<td>4y</td>
<td>M</td>
<td>EDMS</td>
<td>Delayed</td>
<td>4w</td>
<td>Tonic with focal features</td>
<td>Severe ID</td>
<td>Asymmetric tonic Focal motor Focal NCSE</td>
<td>Ongoing</td>
<td>Migration of rhythmic left predominant 2-4 Hz bi-occipital activity to-right 5-6 Hz theta activity L&gt;R posterior quadrant slowing</td>
<td></td>
</tr>
<tr>
<td>EG1519</td>
<td>12y</td>
<td>F</td>
<td>EDEE</td>
<td>Delayed</td>
<td>1d</td>
<td>CSE</td>
<td>Moderate ID</td>
<td>2 additional CSE at 14th and 24th without intervening seizures Tonic with R hemifacial clonic and L eye deviation</td>
<td>Ongoing</td>
<td>Bi-frontal, L fronto-central and temporal slowing</td>
<td></td>
</tr>
<tr>
<td>EPGF011141</td>
<td>19y</td>
<td>F</td>
<td>EDEE → LGS</td>
<td>Unremarkable</td>
<td>1h</td>
<td>Myoclonic</td>
<td>Severe ID</td>
<td>Regression</td>
<td>Tachyphoeptic episode Tonic Focal Impaired awareness CSE Drop attacks Myoclonic (reflex to loud noise) Tonic</td>
<td>Ongoing</td>
<td>GSW PSW Generalised slowing</td>
</tr>
</tbody>
</table>

ACTH, adrenocorticotropic hormone; ADHD, attention deficit hyperactivity disorder; AZD, acetazolamide; CBZ, carbamazepine; CC, corpus callosum; CLB, clonazepam; CLZ, clorazepate; C, cerebral spinal fluid; CT, computed tomography; CSE, convulsive status epilepticus; CZP, clonazepam; d, days; DZP, diazepam; EE, epileptic encephalopathy; EJEE, early infantile migrating focal seizures; EME, early myoclonic encephalopathy; EEOEE, early onset epileptic encephalopathy; ETX, ethosuxamide; F, female; FBM, felbamate; FIS, focal impaired onset; GORD, gastro-oesophageal reflux disease; GPF, generalised paroxysmal fast activity; GSW, generalised spike wave; h, hours; ID, intellectual disability; IS, infantile spasms; KF, levetiracetam; LTG, lamotrigine; LGS, Lennox-Gastaut Syndrome; M, male; MAD, modified Atkins diet; MDZ, midazolam; mth, months; NCSE, non-convulsive status epilepticus; NIM, nicotine; NOG, nitrazepam; OCBZ, oxcarbazepine; PB, phenobarbitone; PFA, paroxysmal fast activity; PHT, phenytoin; PRM, primidone; PSW, polyspike wave; PEG, percutaneous endoscopic gastrostomy; PG, pseudogigantism; SGE, symptomatic generalised epilepsy; SPECT, single-photon emission computed tomography; STP, stiripentol; SSW, slow spike wave; TPM, topiramate; VGB, vigabatrin; VNS, vagus nerve stimulation; weeks; y, years; ZNS, zonisamide

* medications current at last follow-up underlined
Authors
Candace T. Myers¹, Jacinta M. McMahon², Amy L. Schneider², Slavé Petrovski²,³,⁴, Andrew S. Allen⁵, Gemma L. Carvill¹, Matthew Zemel¹, Julia E. Saykally¹, Amy J. LaCroix¹, Erin L. Heinzen³, Georgina Hollingsworth², Marina Nikanorova⁶, Mark Corbett⁷, Jozef Gecz⁸, David Coman⁹, Jeremy L. Freeman¹⁰, Sophie Calvert¹¹, Deepak Gill¹², Patrick Carney¹³, Tally Lerman-Sagie¹⁴, Hugo Sampaio¹⁵, Patrick Cossette¹⁶, Norman Delanty¹⁷, Dennis Dlugos¹⁸, Evan E. Eichler¹⁹, Michael P. Epstein²⁰, Tracy Glauser²¹, Michael R. Johnson²², Ruben Kuzniecky²³, Anthony G. Marson²⁴, Terence J. O’Brien⁴, Ruth Ottman²⁵, Steven Petrou²⁶, Annapurna Poduri²⁷, William O. Pickrell²⁸, Seo-Kyung Chung²⁹, Mark I. Rees²⁸, Elliott Sherr²⁹, Lynette G. Sadleir³⁰, David B. Goldstein³, Daniel H. Lowenstein³¹, Rikke S. Møller⁶, Samuel F. Berkovic², Ingrid E. Scheffer²,²⁶,³², Heather C. Mefford¹

Affiliations
¹ Department of Pediatrics, Division of Genetic Medicine, University of Washington, Seattle, WA
² Epilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, 3084, Australia.
³ Institute for Genomic Medicine, Columbia University, New York, New York 10032, USA
⁴ Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, 3050, Australia
⁵ Department of Biostatistics and Bioinformatics, Duke Clinical Research Institute, and Center for Human Genome Variation, Duke University Medical Center, Durham, North Carolina 27710 USA
⁶ Danish Epilepsy Center, Dianalund, Denmark
⁷ School of Medicine, and the Robinson Research Institute, the University of Adelaide, Adelaide, SA 5000, Australia
⁸ School of Medicine, and the Robinson Research Institute, the University of Adelaide, Adelaide, SA 5000, Australia
⁹ Neurosciences Department, The Lady Cilento Children’s Hospital, Brisbane, School of Medicine, The University of Queensland, Brisbane, School of Medicine, Griffith University, Gold Coast
¹⁰ Murdoch Childrens Research Institute, University of Melbourne, Australia
¹¹ Children’s Health Queensland Hospital and Health Service
¹² TY Nelson Department of Neurology, The Children’s Hospital at Westmead, Sydney, Australia
¹³ The Florey Institute of Neuroscience and Mental Health, Austin Campus, Heidelberg, Victoria, Australia, Austin Health, Heidelberg, Victoria, Australia
Pediatric Neurology Unit, Wolfson Medical Center, Holon, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Department of Paediatric Neurology, Sydney Children’s Hospital, Sydney, Australia

Centre of Excellence in Neuromics and CHUM Research Center, Université de Montréal, CHUM-Hôpital Notre-Dam Montréal, Quebec H2L 4M1e, Canada

Department of Neurology, Beaumont Hospital and Royal College of Surgeons, Dublin 9 Ireland

Departments of Neurology and Pediatrics, The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania

Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA & Howard Hughes Medical Institute, Seattle, WA 98195, USA

Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio 45229 USA

Centre for Clinical Translation Division of Brain Sciences, Imperial College London, London, SW7 2AZ United Kingdom.

NYU Epilepsy Center, Depart of Neurology, New York University

Department of Molecular and Clinical Pharmacology, University of Liverpool, Clinical Sciences Centre, Lower Lane, Liverpool, L9 7LJ, United Kingdom.

Departments of Epidemiology and Neurology, and the G.H. Sergievsky Center, Columbia University; and Division of Epidemiology, New York State Psychiatric Institute, New York, New York 10032 USA.

Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC 3010, Australia.

Division of Epilepsy and Clinical Neurophysiology, Department of Neurology Boston Children’s Hospital, Boston, Massachusetts 02115 USA.

Neurology and Molecular Neuroscience Research, Institute of Life Science, Swansea University Medical School, Swansea University SA2 8PP, United Kingdom

Departments of Neurology, Pediatrics and Institute of Human Genetics, University of California, San Francisco, San Francisco, California 94158 USA.

Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand

Department of Neurology, University of California, San Francisco, San Francisco, California 94143 USA

Department of Paediatrics, Royal Children’s Hospital, The University of Melbourne, Parkville, Victoria, 3050, Australia